别嘌醇对血液透析患者左心室质量指数影响的随机对照试验
本研究为随机双盲安慰剂对照多中心试验,纳入80例维持性血液透析患者,随机接受12个月别嘌醇300mg或安慰剂治疗。主要终点为心脏磁共振成像评估的左心室质量指数变化,结果显示别嘌醇未逆转左心室质量指数,对血压、血流介导扩张、增强指数及脉搏波速度亦无影响。
要点
- 别嘌醇300mg隔次透析后给药12个月未逆转血液透析患者左心室质量指数。
- 别嘌醇对血压、血流介导扩张、增强指数及脉搏波速度无显著影响。
- 该试验为随机双盲安慰剂对照多中心设计,但完成主要终点分析者仅53例。
核心结论
- 与安慰剂相比,别嘌醇治疗未逆转血液透析患者的左心室质量指数。
研究设计与样本
- 随机、安慰剂对照、双盲、多中心试验,由英国心脏基金会资助。
- 从英国苏格兰三个NHS区域招募80例规律维持性血液透析患者,按1:1随机分配。
- 干预为每次透析后别嘌醇300mg或安慰剂,疗程12个月。
- 主要终点为基线及12个月心脏磁共振成像评估的左心室质量指数变化。
主要发现
- 完成研究并有心脏磁共振成像随访数据者53例,平均年龄58岁。
- 左心室质量指数变化:安慰剂组+3.6 ± 10.4 g/m2,别嘌醇组+1.6 ± 11 g/m2,P = 0.49。
- 别嘌醇对血压、血流介导扩张、增强指数及脉搏波速度均无显著影响。
关键数值与推荐
- 别嘌醇剂量为300mg,每次透析后给药,疗程12个月。
- 主要终点左心室质量指数变化组间比较P = 0.49,未达统计学显著性。
临床怎么用
- 不推荐以逆转左心室质量指数为目的对血液透析患者常规使用别嘌醇300mg隔次透析后给药。
- 别嘌醇在该人群中对血压及血管功能指标无显著改善,决策时应结合其他适应证。
局限性
- 完成主要终点分析者仅53例,样本量有限。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Increased left ventricular mass index (LVMI) is associated with mortality in end-stage renal disease. LVMI regression may improve outcomes. Allopurinol has reduced LVMI in randomized controlled trials in chronic kidney disease, diabetes, and ischemic heart disease. This study investigated whether allopurinol would regress LVMI in hemodialysis patients. METHODS: This was a randomized placebo-controlled double-blind multicenter trial funded by the British Heart Foundation (PG/12/72/29743). A total of 80 patients undergoing regular maintenance hemodialysis were recruited from NHS Tayside, NHS Greater Glasgow and Clyde and NHS Ayrshire and Arran in Scotland, UK. Participants were randomly assigned on a 1:1 ratio to 12 months of therapy with allopurinol 300 mg or placebo after each dialysis session. The primary outcome was change in LVMI, as assessed by cardiac magnetic resonance imaging (CMRI) at baseline and 12 months. Secondary outcomes were change in BP, flow-mediated dilation (FMD), augmentation indices (AIx), and pulse wave velocity (PWV). RESULTS: A total of 53 patients, with a mean age of 58 years, completed the study and had CMRI follow-up data for analysis. Allopurinol did not regress LVMI (change in LVMI: placebo +3.6 ± 10.4 g/m2; allopurinol: +1.6 ± 11 g/m2; P = 0.49). Allopurinol had no demonstrable effect on BP, FMD, AIx, or PWV. CONCLUSION: Compared with placebo, treatment with allopurinol did not regress LVMI in this trial.
引用
- Rutherford E, Ireland S, Mangion K, et al. A Randomized, Controlled Trial of the Effect of Allopurinol on Left Ventricular Mass Index in Hemodialysis Patients. Kidney Int Rep. 2020. PMID: 33426394. doi:10.1016/j.ekir.2020.10.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。